This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

One Hour Preoperative Gatifloxacin

This study has been completed.
Information provided by (Responsible Party):
Christopher Ta, Stanford University Identifier:
First received: July 5, 2006
Last updated: January 26, 2015
Last verified: January 2015
Comparison of 1 day versus 1 hour application of topical Zymar.

Condition Intervention Phase
Ophthalmic Surgery Drug: Zymar Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: One Hour Preoperative Gatifloxacin

Resource links provided by NLM:

Further study details as provided by Christopher Ta, Stanford University:

Primary Outcome Measures:
  • Number of Participant With Positive Culture [ Time Frame: 2 weeks ]

Enrollment: 60
Study Start Date: January 2007
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 hour gatifloxacin
presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
Drug: Zymar
zymar qid
Other Name: gatifloxacin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ophthalmic surgery

Exclusion Criteria:

  • taken antibiotics, allergic to fluoroquinolones
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00350363

United States, California
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Responsible Party: Christopher Ta, PI, Stanford University Identifier: NCT00350363     History of Changes
Other Study ID Numbers: 5004
Study First Received: July 5, 2006
Results First Received: May 15, 2014
Last Updated: January 26, 2015

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Nucleic Acid Synthesis Inhibitors processed this record on July 28, 2017